Introduction
The NM23 gene is a conspicuous metastasis-suppressor gene. Expression of the gene correlated inversely with metastatic potential (Steeg et al. 1988) . Bevilacqua et al. (1989) found that NM23 RNA levels were differentially expressed in human breast tumors and that low NM23 RNA levels were associated with histopathologic indications of high metastatic potential. NM23 is a heterodimeric protein that acts as a nucleoside diphosphate (NDP) kinase (Gilles et al. 1991) that catalyzes phosphoryl transfer from a nucleoside triphosphate to an NDP. It is ubiquitously found in organisms from bacteria to human. NDP kinases are involved in the synthesis of nucleoside triphosphates, and the NM23 protein may act in the regulation of signal transduction by complexing with G proteins, causing activation/inactivation of developmental pathways (Stahl et al. 1991) . Eight human genes of the NM23/NDP kinase family have been discovered from analysis of their sequences .
The two most widely studied genes, NM-23H1 and NM23-H2, encode the A and B polypeptide chains of the enzyme. Each chain consists of 152 amino acid residues. The cDNA of NM23-H2 predicts a protein of molecular weight 17 kDa, with 88% identity to NM23-H1. Northern blot hybridization indicated that the expression of NM23-H2 was reduced to a lesser metastatic potential in tumor cells than that of NM23-H1. Both proteins are independently active NDP kinases and readily form intra-and intermolecular disulfide bonds (Stahl et al. 1991) . Both NM23-H1 and NM23-H2 were assigned to 17q21.3 by somatic cell hybrid analysis and fluorescence in situ hybridization (Backer et al. 1993 ) and were 4 kb apart on the chromosome (De la Rosa et al. 1995) .
Materials and methods
A high-quality cDNA library was constructed with a modified pBluescrip II SK (ϩ) vector by using 18-week-old human fetal brain mRNA (Clontech, Palo Alto, CA, USA).
A 0.5-kb DNA fragment containing Sfi (5Ј-GGCCATTA TGGCC-3Ј) and SfiB (5Ј-GGCCGCCTCGGCC-3Ј) recognition sites was cloned into EcoRI and NotI sites of pBluescript II SK (ϩ) (Stratagene, La Jolla, CA, USA); the modified vector was then digested by SfiI and the large fragment was excised and purified for library construction. A cDNA library was constructed by following the SMART polymerase chain reaction (PCR) cDNA library construction kit protocol (Clontech). The cDNA inserts were sequenced on an ABI PRISM 377 DNA sequencer (Perkin-Elmer, San Francisco, CA, USA) using the BigDye Terminator Cycle Sequencing Kit and BigDye Primer Cycle Sequencing Kit (Perkin-Elmer) with Ϫ21M13 primer. An M13Rev primer and synthetic internal walking primers were designed according to the obtained cDNA sequence fragments. Each part of the inset was sequenced at least three times bidirectionally. Subsequent editing and assembly of all the sequences from one clone was performed using Acembly (Sanger Centre Cambs, UK). From our largescale sequencing analysis of human cDNA libraries, we cloned a full-length cDNA encoding a homologue of the mouse NM23 gene and human NM23-H1. The cDNA consisted of 987 bp and contained an open reading frame (ORF) of 534 bp (from 238 bp to 771 bp) encoding a protein of 177 amino acids. The cDNA was considered to be full length because there was an upstream in-frame stop codon (TAA) and a Kozak sequence. The nucleotide sequence has been submitted to the Genbank/EMBL Database with accession number AF487339.
Results
Bioinformatics analysis using BLASTn (http:// www.ncbi.nlm.nih.gov/BLAST) showed that from 89 bp to 305 bp of AF487339 do not exist in NM23-H1 (BC000293, BC018994, NM-000269, X17620, BC008015, AL360166, AL360191, X73066). Interestingly, BLASTp revealed that the cDNA contained an additional NH 2 -terminal region (25 amino acids), whereas the rest was the same as NM23-H1. There was a casein kinase II phosphorylation site motif (SSCD; 19-22 amino acids) in the additional NH 2 -terminal region (http://www.expasy.ch/prosite). Various levels of homology with NM23-H2, NM23-H3, NM23-H4, NM23 (mouse), and NM23 (rat) were also detected ( Fig. 1) .
To determine the chromosomal localization of AF487339, we used the international human genome To further verify that NM23-H1B was a different transcript than NM23-H1A and to confirm the difference of expression between NM23-H1B and NM23-H1A, tissue distribution was determined by multiple tissue cDNA (MTC) panel (Clontech) and human tumor panel (Clontech) as PCR templates according to the manufacturer's protocol. On the basis of bioinformatics analysis, we designed specific primers, including the ORF of the transcript, so that the results of PCR should be NM23-H1B sequences and not NM23-H1A sequences. The sequences for NM23-H1B specific primer pairs were 5Ј-CAGGAGTAAATCAGCCTG GTGTGCAG-3Ј (F, from 121 bp to 146 bp, which do not reside on NM23-H1A cDNA) and 5Ј-GAGAACTCACAG CTCCAAGAGCTTCC-3Ј (R, from 883 bp to 908 bp). The sequences for NM23-H1A specific primer pairs were 5Ј-GTTCAAACCTAAGCAGCTGGAAG-3Ј(F) and 5Ј-CTCCTGTCATTCATAGATCCAGTTCTGA-3Ј(R). The prospective transcript band of NM23-H1B was 788 bp and that of NM23-H1A was 493 bp. Thirty-six cycles of amplification (30 s at 94°C, 1 min at 60°C, and 1 min at 72°C) were performed using ELONGGASE DNA polymerase (Gibco Brl, Gaithersburg, MD, USA). The PCR product of the transcript was then resolved on 1.5% Metaphor agarose gel (FMC, Philadelphia, PA, USA). In total, 16 normal human tissues and 8 human tumor tissues were tested and the specific bands were accorded a prospective length (Fig.  2a) . The data showed that NM23-H1B was ubiquitously expressed in normal tissues (15 tissues except colon) at different levels. In the human tumor panel, we found the specific bands of NM23-H1B in colon adenocarcinoma CX-1, colon adenocarcinoma GI-112, lung carcinoma LX-1, lung carcinoma GI-117, and prostatic adenocarcinoma PC3 (Fig. 2b) . The specific bands of NM23-H1A were found in heart, brain, placenta, lung, liver, skeletal muscle, pancreas, spleen, and thymus, whereas no specific bands of NM23-H1A could be detected in kidney, prostate, testis, ovary, small intestine, and peripheral blood leukocytes (Fig. 2a) . In the human tumor panel, we found specific bands of NM23-H1A in poorly differentiated lung carcinoma GI-117, poorly differentiated colon adenocarcinoma GI-112, and undifferentiated ovarian carcinoma GI-102 (Fig. 2b) .
Discussion
NM23-NDP Kinases are distributed ubiquitously, although their expression may vary in a differentiation-and tissuespecific manner. Early studies showed that NM23 was implicated in cell proliferation, differentiation, and cancer. NM23-H1 is a potential negative regulator of growth factor genes, whereas NM23-H2 is a positive regulator of the cmyc gene, itself crucial to cell growth and differentiation (De la Rosa et al. 1995; Postel et al. 1993) . Current work shows that the human NDP kinase genes are differentially expressed in tissues and that their products are targeted to different subcellular locations. Data suggest that NM23/ NDP kinases possess different, but specific, functions within the cell, depending on their localization . Tumor suppressor genes have a pivotal role in normal cells, regulating cell cycle processes negatively. Furthermore, the inhibition of cell proliferation is a crucial step in the achievement of cell differentiation. Increasing evidence suggests that the NM23 genes, initially documented as suppressors of the invasive phenotype in some cancer types, are involved in the control of normal development and differentiation (Lombardi et al. 2000) .
We report here a different transcript (NM23-H1B) of human NM23-H1A from our large cDNA cloning and sequencing project. The gene is 987 bp long and encodes a protein of 177 amino acid residues, which is the same as the NM23H1A protein except for an additional NH 2 -terminal region (25 amino acids). Bioinformatics analysis indicates that the NM23-H1B gene is mapped to chromosome 17q21.3. It has six exons and five introns, but the second exon is missing in NM23-H1A. For tissue distribution, our The intron sequence is shown in lowercase letters and the exon sequence in uppercase letters a Exon 2 does not exist in NM23-H1 cDNA data reveal a transcript in brain, placenta, liver, skeletal muscle, ovary, and peripheral blood leukocytes. Expression is lower in heart, lung, kidney, pancreas, spleen, thymus, prostate, testis, and small intestine. No specific band can be detected in colon. Our data also indicate that the expression of NM23-H1B is related to tumor differentiation: in poorly differentiated breast carcinoma GI-101, pancreatic adenocarcinoma GI-103, and undifferentiated ovarian carcinoma GI-102, there is no expression. In poorly differentiated lung carcinoma LX-1, lung carcinoma GI-117, the expression level is low. The transcript band in well-differentiated colon adenocarcinoma CX-1 is significantly higher than that in poorly differentiated colon adenocarcinoma GI-112, but it is also expressed highly in grade IV prostatic adenocarcinoma PC3. We also detected the expression of NM23-H1A. Our data showed that there is a difference between NM23-H1B and NM23-H1A in human normal panel and in human tumor panel. Further studies will focus on the protein function of NM23-H1B. 
